FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:614-619 March 4, 1993 Number 9 Next

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background and Methods A characteristic of acute myeloid leukemia is the frequent ability of the leukemic cells to sustain their own proliferation in vitro. To determine the clinical importance of this property, we measured the uptake of tritiated thymidine by leukemic cells in serum-free and cytokine-free cultures as a means of determining the rate of spontaneous proliferation in 114 patients with newly diagnosed acute myeloid leukemia. Proliferation was then classified according to three quantitative levels of activity and related to overall survival and to treatment outcome (the response to treatment, the actuarial probability of relapse, and disease-free survival) in 91 patients who were treated with chemotherapy to induce remission.

Results Of the 114 patients, 37 had low, 39 had intermediate, and 38 had high levels of proliferation. The probability of survival at three years was 36 percent among patients with low levels of proliferative activity and 3 percent among those with high levels (P<0.001). Among the patients treated with chemotherapy, those with low rates of proliferative activity had a 68 percent rate of complete remission and a 49 percent probability of remaining free of relapse, whereas those with high rates of proliferative activity had only a 39 percent rate of complete remission (P = 0.04) and an 11 percent probability of remaining in complete remission (P = 0.009). The probability of disease-free survival at three years among the patients in complete remission after chemotherapy was 49 percent among those with low rates of proliferative activity and 9 percent among those with high rates (P = 0.004). Accordingly, patients with low rates of proliferative activity also had a significantly higher rate of overall survival (44 percent vs. 4 percent; P = 0.002). Patients whose cells had intermediate levels of proliferation in vitro had intermediate rates of survival, relapse, and disease-free survival.

Conclusions The capacity of leukemic blasts for autonomous proliferation is associated with highly aggressive acute myeloid leukemia. .

Source Information

From Dr. Daniel den Hoed Cancer Center (B.L., W.L.J.v.P., I.P.T., V.S.) and Erasmus University (B.L., R.D.), Rotterdam, the Netherlands.

Address reprint requests to Dr. Lowenberg at Dr. Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, the Netherlands.

Full Text of this Article

This article has been cited by other articles:

• Gozzini, A., Rovida, E., Dello Sbarba, P., Galimbert, S., Santini, V. (2003). Butyrates, as a Single Drug, Induce Histone Acetylation and Granulocytic Maturation: Possible Selectivity on Core Binding Factor-Acute Myeloid Leukemia Blasts. Cancer Res. 63: 8955-8961 [Abstract] [Full Text]  
• Efferth, T., Sauerbrey, A., Olbrich, A., Gebhart, E., Rauch, P., Weber, H. O., Hengstler, J. G., Halatsch, M.-E., Volm, M., Tew, K. D., Ross, D. D., Funk, J. O. (2003). Molecular Modes of Action of Artesunate in Tumor Cell Lines. Mol. Pharmacol. 64: 382-394 [Abstract] [Full Text]  
• Faderl, S., Harris, D., Van, Q., Kantarjian, H. M., Talpaz, M., Estrov, Z. (2003). Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood 102: 630-637 [Abstract] [Full Text]  
• Erkeland, S. J., Valkhof, M., Heijmans-Antonissen, C., Delwel, R., Valk, P. J. M., Hermans, M. H. A., Touw, I. P. (2003). The gene encoding the transcriptional regulator Yin Yang 1 (YY1) is a myeloid transforming gene interfering with neutrophilic differentiation. Blood 101: 1111-1117 [Abstract] [Full Text]  
• Testa, U., Riccioni, R., Militi, S., Coccia, E., Stellacci, E., Samoggia, P., Latagliata, R., Mariani, G., Rossini, A., Battistini, A., Lo-Coco, F., Peschle, C. (2002). Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 100: 2980-2988 [Abstract] [Full Text]  
• van den Heuvel-Eibrink, M. M., Wiemer, E. A. C., de Boevere, M. J., van der Holt, B., Vossebeld, P. J. M., Pieters, R., Sonneveld, P. (2001). MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 97: 3605-3611 [Abstract] [Full Text]  
• Roelofs, H., Mostert, M. C., Pompe, K., Zafarana, G., van Oorschot, M., van Gurp, R. J. H. L. M., Gillis, A. J. M., Stoop, H., Beverloo, B., Oosterhuis, J. W., Bokemeyer, C., Looijenga, L. H. J. (2000). Restricted 12p Amplification and RAS Mutation in Human Germ Cell Tumors of the Adult Testis. Am. J. Pathol. 157: 1155-1166 [Abstract] [Full Text]  
• Banker, D. E., Groudine, M., Norwood, T., Appelbaum, F. R. (1997). Measurement of Spontaneous and Therapeutic Agent-Induced Apoptosis With BCL-2 Protein Expression in Acute Myeloid Leukemia. Blood 89: 243-255 [Abstract] [Full Text]  
• Pui, C.-H. (1995). Childhood Leukemias. NEJM 332: 1618-1630 [Full Text]